Cargando…

Non-inhibitory antibodies inducing increased emicizumab clearance in a severe hemophilia A inhibitor patient

Detalles Bibliográficos
Autores principales:	Harroche, Annie, Sefiane, Thibaud, Desvages, Maximilien, Borgel, Delphine, Lasne, Dominique, Casari, Caterina, Peyron, Ivan, Frenzel, Laurent, Chhun, Stéphanie, Lenting, Peter J., Bally, Cécile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327735/ https://www.ncbi.nlm.nih.gov/pubmed/34011136 http://dx.doi.org/10.3324/haematol.2021.278579

Ejemplares similares

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab
por: Inoue, Fumiya, et al.
Publicado: (2022)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Management of children with hemophilia A on emicizumab who need surgery
por: Belletrutti, Mark, et al.
Publicado: (2023)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report
por: Al-Banaa, Kadhim, et al.
Publicado: (2019)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
por: Le Quellec, Sandra
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A
por: Iarossi, Michael, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023)

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
por: Zhou, Zheng-Yi, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
por: Yang, Renchi, et al.
Publicado: (2022)

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study
por: Donners, Anouk A. M. T., et al.
Publicado: (2022)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor
por: Wohner, Nikolett, et al.
Publicado: (2018)

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
por: Warren, Beth Boulden, et al.
Publicado: (2021)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

PB2643: EFFICACY OF REDUCED-DOSE EMICIZUMAB IN HEMOPHILIA A WITH INHIBITORS: REAL WORLD EXPERIENCE IN MALAYSIA
por: Tang, Andy Sing Ong, et al.
Publicado: (2023)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
por: Rener, Karla, et al.
Publicado: (2023)

Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
por: Glonnegger, Hannah, et al.
Publicado: (2022)

Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
por: Kizilocak, Hande, et al.
Publicado: (2019)

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors
por: Okamoto, Shuichi, et al.
Publicado: (2019)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report
por: Ahn, Ji Hyun, et al.
Publicado: (2021)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
por: Batsuli, Glaivy, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
por: Retout, Sylvie, et al.
Publicado: (2020)

A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
por: Yoneyama, Koichiro, et al.
Publicado: (2021)

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
por: Kruse-Jarres, Rebecca, et al.
Publicado: (2022)

Peri‐operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis
por: Yagyuu, Takahiro, et al.
Publicado: (2022)

Emicizumab-induced photosensitivity
por: Asensi Cantó, Pedro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d7k4ua0dlssnsrme0afbtgquti